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Abstract
Beneficial effects of dehydroepiandrosterone (DHEA) supplement on age-associated chronic diseases such as cancer, cardiovascular disease, insulin
resistance and diabetes, have been reported. However, its mechanism of action in hepatocellular carcinoma in vivo has not been investigated in 
detail. We have previously shown that during hepatocellular carcinogenesis, DHEA treatment decreases formation of preneoplastic glutathione S-transferase
placental form-positive foci in the liver and has antioxidant effects. Here we aimed to determine the mechanism of actions of DHEA, in comparison
to vitamin E, in a chemically-induced hepatocellular carcinoma model in rats. Sprague-Dawley rats were administered with control diet without
a carcinogen, diets with 1.5% vitamin E, 0.5% DHEA and both of the compounds with a carcinogen for 6 weeks. The doses were previously
reported to have anti-cancer effects in animals without known toxicities. With DHEA treatment, cytosolic malate dehydrogenase activities were significantly
increased by ~5 fold and glucose 6-phosphate dehydrogenase activities were decreased by ~25% compared to carcinogen treated group. Activities 
of Se-glutathione peroxidase in the cytotol was decreased significantly with DHEA treatment, confirming its antioxidative effect. However, liver
microsomal cytochrome P-450 content and NADPH-dependent cytochrome P-450 reductase activities were not altered with DHEA treatment. Vitamin
E treatment decreased cytosolic Se-glutathione peroxidase activities in accordance with our previous reports. However, vitamin E did not alter glucose
6-phosphate dehydrogenase or malate dehydrogenase activities. Our results suggest that DHEA may have decreased tumor nodule formation and
reduced lipid peroxidation as previously reported, possibly by increasing the production of NADPH, a reducing equivalent for NADPH-dependent 
antioxidant enzymes. DHEA treatment tended to reduce glucose 6-phosphate dehydrogenase activities, which may have resulted in limited supply
for de novo synthesis of DNA via inhibiting the hexose monophophaste pathway. Although both DHEA and vitamin E effectively reduced preneoplastic
foci in this model, they seemed to function in different mechanisms. In conclusion, DHEA may be used to reduce hepatocellular carcinoma growth
by targeting NADPH synthesis, cell proliferation and anti-oxidant enzyme activities during tumor growth.
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Introduction5)
DHEA and DHEA-sulfate are the precursors of androgens and 
estrogens produced from adrenal glands (Roberge et al., 2007). 
Their levels start to decrease after middle age and animal and 
human studies have reported that age-associated chronic diseases 
involving dysregulation of metabolism may be due to the decline 
in the levels of these compounds (Labrie, 2007). Although there 
have been in vivo studies about the protective effects of DHEA 
against cancer, obesity, diabetes, postmenopausal osteoporosis, 
sexual dysfunction and cardiovascular disease as modulators of 
adrenocortical steroid synthesis (Allolio et al., 2007; Kim and 
Choi, 2005), its mechanism of action needs to be studied more 
in detail before safely used as supplements in humans for 
different diseases. 
Reactive oxygen species are continuously formed as by-pro-
ducts of aerobic metabolism and from reactions of drugs and 
environmental toxins such as carcinogens (Cerutti, 1985). These 
play important roles in tumor progression by damaging DNA, 
proteins and unsaturated lipids (Champe & Harvey, 1987). The 
cells have protective mechanisms that can minimize the toxic 
effects from these compounds. These mechanisms include 
antioxidant chemicals (e.g. vitamin E), enzymes that catalyze 
antioxidant reactions using NADPH as a source of reducing 
electrons and a liver microsomal cytochrome P-450 mono- 
oxygenase system, which also utilizes NADPH to convert 
steroids and drugs to soluble forms (Wu et al., 1989). 
We have previously shown that DHEA decreases glutathione 
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S-transferase placental from (GST-p) foci in the liver and lipid 
peroxdation using a hepatocellular carcinoma model in rats 
(Kim & Choi, 2005). Here, we aimed to determine the 
mechanism of protective effects of DHEA supplement during 
chemical hepatocellular carcinogenesis in vivo in comparsion to 
those with vitamin E supplement, an effective intracellular 
reducing agent. 
Materials and Methods
Animals 
Six-week-old male Sprague Dawley rats were purchased from 
Seould National University and
  housed at the animal care facility 
at Seoul National University (Seoul, Korea). All rats
  were kept 
under standard temperature, humidity, and timed lighting
 
conditions and were provided with rat chow and water ad libitum. 
Animals were induced with hepatocellular carcinoma by i.p. 
injection of diethylnitrosamine (200 mg/kg body weight) 
followed by administration of diets containing 0.01% of 
2-acetylaminofluorene for 6 weeks. Partial hepatectomy surgeries 
were performed 1 week after the start of 2-acetylaminofluorene 
diet to effectively induce progression of tumor as previously 
published (Ito et al., 1988). 
Diets and materials
Rat chow was purchased from Purina (purified rodent diet 
5053, St. Louis, Missouri) and was supplemented with 1.5% 
vitamin E (Sigma T-3376, DL-α tocopheryl acetate, St. Louis, 
MO) and 0.5% DHEA (Sigma D-400, DHEA 3-acetate, St. Louis, 
MO) as described previously (Kim & Choi, 2005).
Biochemical assays
Frech or frozen livers were weighed and five volumes of 
ice-cold homogenization buffer [154 mM KCl, 50 mM Tris-HCl, 
1mM EDTA, pH 7.5] were added. The tissue was homogenized 
and was fractionated by spinning at 1,000 g for 13 min at 4°C. 
The middle layer was centrifugated at 10,000 g for 13 min at 
4°C. Then the supernatant was centrifugated at 100,000 g for 
65 min at 4°C to obtain cytosolic and microsomal fractions as 
described in detail previously (Kim & Choi, 2005). 
Malate dehydrogenase activities 
Malate dehydrogenase activities were measured in the cytosolic 
fraction using modified methods of Ochoa (1969). Briefly, 500 
μl of triethanolamine buffer [0.4 M, pH 7.4], 50μl of L-malate 
[30 mM], 100 μl of MnCl2, 4H2O [0.12 M] and 200μl of NADP 
[3.4 mM] were mixed with 1,400 μl of cytosolic fraction using 
a vortex. Absorption at 270 nm during 1 min at 26℃  was 
measured every 6 seconds. One unit is increased in absoption 
by 0.01 during 1 min. 
Glucose 6-phophate dehydrogenase activities 
Glucose 6-phophate dehydrogenase activities were measured 
in the cytosolic fraction using modified methods of Lohr and 
Waller (1974). Briefly, 2.4 ml of triethanolamine buffer [50 mM, 
pH 7.5] and 0.5 ml of cytosolic fraction (~0.8 mg/ml protein) 
were mixed using a vortex. Then, 50 μl of NADP solution was 
added and was kept at 25℃ for 5 minutes. Next, 50 μl of glucose 
6-phosphate was added and increases in absorption was 
immediately measured at 340 nm for every 2 minutes up to 6 
minutes. Specific activity was calculated as μmole of substrate 
converted per minute per mg protein. 
Se-glutathione peroxidase
Cytosolic Se-glutathione peroxidase activites were measured 
using a modified method of Tappel (1978) as previously 
described. 
Microsomal cytochrome P-450 
Hepatic microsomal fraciton was used to measure cytochrome 
P-450 content (Omura & Sato, 1964). Fresh microsomal fraction 
was diluted with phosphate buffer (pH 7.4) to conatin ~ 1 mg/ml 
protein and sodium dithionate was added and was saturated with 
CO gas for 1 minute. Then, absorptions of reduced carbon 
monoxide at 450 and 490 nm were determined spectrophoto-
metrically. Molar extinction coefficient used was 91/mM/cm.
Protein concentration
Protein concentrations were determined by the Bradford assay 
using the Biorad Protein assay reagent (Biorad, Hercules, CA).
Statistical analysis 
Data are expressed as mean ± SE. SAS software was used for 
Duncan’s multiple range test and one-way ANOVA to determine 
statistical differences (p<0.05).
Results
DHEA treament increased cytosolic malate dehydrogenase 
activities
We previously showed (Kim & Choi, 2005) that DHEA 
treatment decreased NADPH-utilizing antioxidant enzymes in 
this model so we first determined if activities of enzymes that 
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Fig. 1. DHEA treament increases cytosolic malate dehydrogenase activities. 
The level of cytosolic malate dehydrogenase activity was determined by biochmical 
enzymatic  assay.  Hepatocellular  carcinoma  was  induced  with  diethylnitrosamine, 
2-acetylaminofluorene and ~70% partial hepatectomy using male Sprague-Dawley 
rats. The animals were treated with control diet without a carcinogen, carcinogen 
diets with 1.5% vitamin E, 0.5% dehydroepiandrosterone (DHEA) and both 1.5% 
vitamin E and 0.5% DHEA. After ultracentrifugation of freshly-obtained liver, cytosolic 
fraction  was  obtained  and  used  to  measure  malate  dehydrogenase  activities. 
Activities were normlaized against protein concentration. One-way ANOVA test was 
used to determine significance (n=6~9 each). Means with different subscripts are 
significantly  different  at  p<0.05  by  Duncan’s  multiple  range  test. 
Fig. 2. Activities of cytosolic glucose 6-phosphate dehydrogenase tended to 
decrease with DHEA treatment. The level of glucose 6-phosphate dehydrogenase
activity  was  determined  by  biochmical  enzymatic  assay.  Similar  t o  t h e  m a l a t e  
dehydrogenase, after ultracentrifugation of freshly-obtained liver, cytosolic  fraction 
was obtained and used to measure glucose 6-phosphate dehydrogenase activities. 
Activities were normalized against protein concentration. One-way ANOVA test was 
used to determine significance (n=6~9 each). Means with different subscripts are 
significantly  different  at  p<0.05  by  Duncan’s  multiple  range  test. 
treatment significantly increased malate dehydrogenase activities 
by almost 5 fold vs. carcinogen-treated controls (Fig. 1). This 
effect was not seen in vitamin E-treated animals. Malate 
dehydrogenase activities were not different between non-carcn-
inogen treated and carcinogen-treatd groups (Fig. 1, COO vs. 
TOO). Based on these results, we focused our study on 
determining the activities of another NADPH producing enzyme, 
glucose 6-phosphate dehydrogenase. a and b; one-way ANOVA, 
p<0.05
Activities of cytosolic glucose 6-phosphate dehydrogenase had 
a tendency to decrease with DHEA treatment
Although DHEA treatment increased malate dehydrogenase 
activities, it had a strong tendency to decrease glucose 6-phos-
phate dehydrogenase activities (Fig. 2). Glucose 6-phosphate 
dehydrogenase activity was increased by almost 1.5 fold with 
the carcinogen treatment and DHEA supplement decreased it to 
the level of those of non-carcinogen treated group (COO vs. 
TOD). However, in the combination group (TED), the enzyme 
activity was not suppressed as seen in DHEA-only treated 
animals. a, b, c; one-way ANOVA, p<0.05.
DHEA treatment decreased hepatic cytosolic Se-glutathione 
peroxidase activities.
Activities of cytosolic Se-glutathione peroxidase activities 
tended to increase with carcinogen treatment (COO vs. TOO). 
The enzyme activities were inhibited almost 50-60% with DHEA 
treamtment comapred to controls (COO and TOO vs. TOD). 
Vitamin E treatment also decreased the activities significantly 
and a synergistic inhibitory effects were seen in combination 
treatment group (TOO vs. TED). 
Hepatic microsomal cytochrome P-450 content was not altered 
with DHEA treatment. 
To examine the mechanism of action of DHEA on hepatic 
microsomal cytochrome P-450 mono-oxygenase system, cytoc-
hrome P-450 content was measured. DHEA treatment did not 
affect cytochrome P-450 content (Fig. 4). We also measured 
microsomal NADPH cytochrome P-450 reductase activites but 
they were also not affected with DHEA treatment (data not 
shown). 
Discussion
Here we studied the mechanism of action of DHEA during 
hepatocellular carcinogenesis in vivo. We found that DHEA 
significantly increased activities of malate dehydrogenase, an 
enzyme important for supplying biochemical reductant NADPH 
in the cytosol. On the other hand, glucose 6-phosphate 
dehydrogenase activites were reduced by ~25% with DHEA 
treatment possibly due to the high level of NADPH/NADP
+ ratio 
in the cytosol, provided by increased malate dehydrogenase 
activity. Reports showed that DHEA treatment decreased mRNA 
levels of hepatic malate dehydrogenase in broiler chickens (Zhao 
et al., 2007) and increased the activity in non-insulin dependent 
diabetic rats (Ladriere et al., 1997). However, mRNA levels do 
not always correlate with levels of enzyme activity and the dose, 
duration and the disease model used in these studies were 
different from the current study. Marrero, et al. showed that 
DHEA treatment in female mice increased hepatic malate Jeewon Kim et al. 83
Fig. 3. DHEA treatment decreased hepatic cytosolic Se-glutathione peroxidase 
activities.  Activities  of  Se-glutathione  peroxidase  activities  were  measured  in  the 
hepatic  cytosolic  fractions  as  mentioned  above,  using  hydrogen  peroxide  as 
substrate.  Means  with  different  subscripts  are  significantly  different at p<0.05  by 
Duncan’s  multiple  range  test. 
Fig. 4. Hepatic microsomal cytochrome P-450 content was not different with 
DHEA treatment. Content  of  cytochrome  P-450  was  measured  in  the  hepatic 
microsomal  fractions  using  reduced  carbon  monoxide.  Microsomal  fraction  was 
obtained  as  described  in  the  methods.  One-way  ANOVA  test  was  used  to 
determine  significance  (n=6~9  each).
dehydrogenase activites by 2-3 fold (Marrero et al., 1990) but 
did not alter glucose 6-phosphate dehydrogenase activity, similar 
to the data from this study. Further studies using different organ 
systems in various disases models are needed to clarify effect 
of DHEA on these NADP-dependent enzymes. 
Under most metabolic conditions, the ratio of NADPH/NADP
+ 
is high enough to inhibit glucose 6-phosphate dehydrogenase 
activity. However, with increased demand for NADPH in the 
cells (e.g. toxic and oxidative stress), the ratio of NADPH/NADP
+ 
decreases and flux through the hexose monophosphate pathway 
is enhanced by increasing the activity of glucose 6-phosphate 
dehydrogenase (Champe & Harvey, 1987). Glucose 6-phosphate 
dehydrogenase is the key enzyme regulating the first and 
irreversible step of the pentose phsophate pathway. This pathway 
can then provide ribose-5-phosphates, a precursor for DNA 
synthesis in cell proliferation. During promotional phase of 
carcinogenesis, the demand for ribose-5-phosphate for de novo 
synthesis of DNA may be increased and it is thus particularly 
important that DHEA treatment suppressed this rate limiting 
enzyme of the pentose phosphate pathway, glucose 6-phosphate 
dehydrogenase. This may be one of the protective mechanisms 
of DHEA during carcinogenesis as reported previously (Kim & 
Choi, 2005). Although malate dehydrogenase activites increased 
with DHEA treamtment in this study, it has been reported that 
its activity is ~15% of that of glucose 6-phosphate dehydrogenase 
in rat adrenal cortex (Frederiks et al., 1990). If this is the case 
in rat liver, the decrease in glucose 6-phosphate dehydrogenase 
would surpass the relative change in the malate dehydrogenase 
activity in the inhibition of pentose phosphate pathway. 
Increases in malate dehydrogenase activities by DHEA 
treatment may have also provided NADPH to reduce glutathione 
efficiently. This antioxidant effects of DHEA was seen in 
decreased Se-dependent glutathione peroxidase activities (Fig. 3), 
confirming less oxidative damage with DHEA treatment as 
previously reported (Kim & Choi, 2005). Reduced glutathione 
(a tripeptide-thiol) can detoxify hydrogen peroxide in most cells 
in a NADPH-dependent manner (Frederiks et al., 1990) catalyzed 
by glutathione reductase. Although the cells were producing 
higher amounts of NADPH through malate dehydrogenase, it 
may be that the cells were not triggered to increase NADPH- 
dependent antioxidant enzymes due to already decreasd oxidative 
stress level in the cell by direct or indirect antioxidant effect 
of DHEA. The possible mechanism of the non-enzymatic 
antioxidative activity of DHEA needs further studies in the future. 
Furthermore, the effects of DHEA may depend on the phase in 
which these enzymatic activities were measured during the 
progression of hepatocellular carcinoma.
Vitamin E has been known to be a strong nonenzymic 
antioxidant, preventing oxidative damage in the cell components 
by reducing free radicals as reported (Muller et al., 2003). Here, 
vitamin E decreased glutathione peroxidase activities (Fig. 3) 
probably through different mechanism than that from DHEA; 
vitamin E did not alter malate dehydrogenase or glucose 
6-phosphate dehydrogenase activities in this study. 
Lastly, the content of cytochrome P-450 (Fig. 4) and 
NADPH-dependent cytochrome P-450 reductase activities (data 
not shown) were not affected by DHEA treatment. These data 
suggest that the mechanism of actions of DHEA is independent 
from these liver microsomal cytochrome P-450 mono-oxygenase 
system, a major pathway for the hydroxylation of aromatic and 
aliphatic compounds sush as stroids and alcohols and carcinogens 
(Wu et al., 1989) which also uses NADPH to to convert them 
into soluble forms. This is different from previous reports that 
showed that DHEA decreased cytochrome P-450 enzymes, 
especially P4501A and 3A (Fitzpatrick et al., 2001). It is possible 
that because we measured total levels of cytochrome P-450 in 
this study, we may not have found any difference in the overall 
levels and may have missed isozyme-specific effects of DHEA.
Our data suggest that DHEA has protective effects during 
hepatocellular carcinoma by upregulating NADPH-producing 84 DHEA increases malic enzyme activity in vivo
malate dehydrogenase and may thus spare cells from reactive 
oxygen species-induced damages during carcinogenesis. In the 
future, more studies with different concentration of DHEA in 
various stages of cancer progression will be required to find out 
further details of its mechanism of action in vivo.
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